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Abstract:  
Gait and speech are automatic motor activities which are frequently impaired in 
Parkinson’s disease (PD). Obvious clinical similarities exist between these  disorders but were 
never investigated. We propose to determine whether there exist any common features in PD 
between spatiotemporal gait disorders and temporal speech disorders. 
Gait and speech were analyzed on eleven PP undergoing deep-brain-stimulation of the sub-
thalamic-nucleus (STN-DBS) and eleven control subjects (CS) under 3 conditions of velocity 
(natural, slow and speed). The patients were tested with and without L-Dopa and stimulator 
ON or OFF.  Locomotor parameters were recorded using an optoelectronic system. Speech 
parameters were recorded with a headphone while subjects were reading a short paragraph.  
 The results confirmed that PP walk and read more slowly than controls.  Patient’s 
difficulties in modulating walking and speech velocities seem to be due mainly to an inability 
to internally control the step length and the interpause-speech duration ISD. 
 STN-DBS and levodopa increased patients’ walking velocity by increasing the step length. 
STN-DBS and levodopa had no effect on speech velocity but restored the patients’ ability to 
modulate the ISD. The walking cadence and speech index of rythmicity (SPIR) tended to be 
lower in patients and were not significantly improved by STN-DBS or levodopa. Speech and 
walking velocity as well as ISD and step length were correlated in both groups. Negative 
correlations between SPIR and walking cadence were observed in both groups 
Similar fundamental hypokinetic impairment and probably a similar rhythmic factor 
affected similarly the patients’ speech and gait. These results suggest a similar 
physiopathological process in both walking and speaking dysfunction. 
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Introduction 
Basal ganglia dysfunction leads to the lack of automatic execution of learned motor 
sequences (Marsden, 1982) and to the development of Parkinsonian motor symptoms (Lee et 
al., 1994), including changes in gait and speech.  
 Gait disorders in PD (Hoehn and Yahr, 1967), constitute one of the main factors 
affecting patients’ independence and quality of life (Koplas et al., 1999). PP walk slower, 
with shorter step length and a compensatory increased walking cadence (Blin et al, 1990, 
Morris et al., 1994a, b). Levodopa improves spatiotemporal parameters such as walking 
velocity and step length, but not temporal parameters such as step time, swing time and 
walking cadence (Azulay et al., 1996; Blin et al., 1990; Pedersen et al., 1991). Studies have 
shown that Sub-Thalamic-Nucleus Deep Brain Stimulation (STN-DBS) improves walking 
velocity by increasing the step length without affecting the walking cadence (Faist et al., 
2001; Lubik et al., 2006) while a modulation of cadence has been  reported by others (Stolze 
et al., 2001). 
 Approximately 70% of PP experience speech difficulties attributed to bradykinetic and 
hypokinetic articulatory movements, orofacial hypomimy, rigidity and rest tremor (Hartelius 
and Svensson, 1994). 
 PPs’ speech timing deficits seem to have some points in common with their 
spatiotemporal gait deficits. Speech velocity often decreases in PP (Canter, 1963; Metter and 
Hanson, 1986) just like walking velocity. The interpauses speech duration (ISD) is usually 
shortened in PP (Forrest et al., 1989; Hammen and Yorkston, 1996), in line with the step 
length.  
 PP are subject to dysprosody, and show less variability in the fundamental frequency 
and intensity and more speech velocity and pausing abnormalities than control subjects (CS) 
(Canter, 1963; Harel et al., 2004; Kegl et al., 1999) .  
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 Dysfluent behavior has also been described in PP (Benke et al., 2000), consisting 
mainly of repetitive speech phenomena involving the repetition of syllables, words or phrases. 
Skodda and Schlegel (2008) reported that during a standardized reading task, the speech 
velocity of PP accelerates more strongly while speaking and the total number of pauses 
decreases significantly, which indicates that their speech rhythm and timing organization 
processes are impaired. Physicians often have the feeling that paroxystic speech velocity 
accelerations develop in line with gait festinations and dysrhythmic pauses and that repetitive 
speech phenomenon such as stuttering, iterations and palilalia are somewhat comparable to 
freezing of gait. Few studies have focused on the effects of levodopa on speech timing 
parameters. Levodopa does not improve speech velocity (Wolfe et al., 1975) or stuttering 
(Anderson et al., 1999; Benke et al., 2000). Speech dysfluencies may be due to an increase or 
a decrease in the dopamine levels present in the brain Two studies have shown that selective 
left-side STN-DBS may have negative effects on prosody (Santens et al., 2003; Wang et al., 
2003), but the quantitative effects of STN-DBS on specific temporal speech parameters have 
never been assessed. 
 Our aim was to compare gait and speech patterns of PP and CS, and to analyse the 
patients’ responses to levodopa and STN-DBS. Another aim was to determine whether there 
exist any correlations between the spatiotemporal gait and temporal speech parameters with a 
view to establishing whether, in line with what occurs with gait, hypokinesia may be mainly 
responsible for these patients’ speech timing disorders and whether accelerated timing 
strategies may be used as compensatory mechanisms. 
  
II. MATERIAL AND METHODS 
 
1. Subjects 
 5 
 
Eleven PP, 7 males and 4 females (mean age 64.5) and 11 age-matched CS, 7 males 
and 4 females (mean age 66.3) with no neurological history took part in these experiments 
after giving their informed consent. The project was approved by the local ethical committee. 
All the PP had undergone bilateral STN-DBS and were stable when the study was conducted. 
PP and controls with any other disorder possibly affecting their walking or speaking abilities 
were excluded from the study.  
PPs’ level of functional disability was determined on the Unified Parkinson’s Disease Rating 
Scale (UPDRS) motor and axial scores in four treatment conditions (OFF and ON states of 
STN-DBS and levodopa). The patients’ characteristics are given in Table 1. 
  
2.  Test procedure 
  Gait and speech recordings were conducted in the four treatment conditions, always in 
the same order. Gait recordings were run always just before speech recordings.  
1. PP were tested in the OFF STN-DBS state at least 12 hours after undergoing STN-
DBS treatment and in the OFF levodopa state at least 12 hours after their last dose of 
dopaminergic treatment (DT) (OFF/OFF) 
2.  the PP were tested in the ON STN-DBS state at least 1 hour after undergoing STN-
DBS treatment and in the ON levodopa state at the peak effect of a suprathreshold 
dose of levodopa (ON/ON). 
3. the PP were tested in the ON STN-DBS state at least 12 hours after undergoing STN-
DBS treatment and in the OFF levodopa state at least 12 hours after taking their last 
DT dose (ON/OFF). 
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4. the PP were tested in the OFF STN-DBS state at least 3 hours after undergoing STN-
DBS treatment and in the ON levodopa state at the peak effect of a suprathreshold 
dose of levodopa (OFF/ON). 
  The gait and speech recordings were conducted just once on the CS.  
 
3. Gait recordings 
 3.1 Tasks 
Subjects were instructed to walk on level ground at their natural speed (NS), slowest 
as compared with the first task (SS) and  as fast as possible without running (FS).  
 
3.2 Experimental recordings 
Kinematic analysis was performed with the ELITE TV image processing system 
(Ferrigno and Pedotti, 1985). 22 reflective markers 1 cm in diameter were taped onto the 
subjects’ skin at specific symmetrical anatomical points. The recordings were taken with 6 
TV cameras at a sampling rate of 100 Hz. 
  
 3.3 Gait parameters 
Based on the kinematic recording, temporal and spatial gait parameters were measured 
during each trial: walking velocity (m/s), step length (mm) and walking cadence (step/min). 
4. Speech recordings 
 4.1 Tasks 
Subjects had to read a short printed text at their natural speed (NS), slowest as 
compared with the natural condition (SS) and as fast as possible (FS).  
 
 4.2 Experimental recordings 
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 Subjects were seated in a quiet room. Temporal acoustic recordings obtained via a 
headphone were analyzed using the ProsodyR software program, which is part of the Software 
Environment for Speech Analysis and Evaluation (SESANER).  
 
 4.3 Speech parameters 
Based on the acoustic data the following parameters were measured at each trial:  
- Speech velocity (syllables/second)  
- Interpause speech duration (ISD in seconds): It corresponds to the time interval 
between two pauses. It was determined by tallying the duration occurring between 
two pauses. 
-  Speech Index of Rhythmicity (SPIR): this is an index to evaluate speech rhythmicity 
in the same way as the walking cadence. As the alternation between pauses and speech gives 
rhythm to speech just as the alternation between steps and double foot support phases gives 
rhythm to gait, SPIR corresponds the number of speech interpauses per minute.  
 
5. Statistical procedure 
Because of the small size and the non normal distribution of our samples, all the tests 
applied were non parametric tests. For each subject and condition, all variables have been 
averaged over the three trials. In the OFF/OFF situation, two PP were unable to walk. 
Nevertheless, we have used the data of these patients in the other conditions of treatment. The 
statistics given are medians and interquartiles.  
Differences between CS and PP were tested with a Mann–Whitney U test. The task 
effect in each group and the treatment effect in the PP group were analyzed with a Friedman 
ANOVA. In order to isolate statistical differences when the hypothesis of differences was 
verified we have realised a multiple comparison procedures (post-hoc tests) using a Student-
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Newman-Keuls (SNK) test. The correlations between gait and speech parameters were tested 
with a Spearman test. 
 
RESULTS 
1. Gait analysis 
1.1 Effects of PD 
 In order to assess the effects of PD on gait parameters, the gait characteristics of PP in 
the OFF/OFF state of treatment were compared with those of the CS. 
 Whatever  experimental situations, gait velocity of PP was slower than that of CS (T 
(1.18)=61, p<0.05; T (1.18)=62, p<0.05 and T (1.18)=58, p<0.05 in conditions NS, SS and 
FS, respectively); the mean step length was shorter (T (1.18)=57, p<0.01; T (1.18)=59, p<0.01 
and T(1.18)=59, p<0.01 in conditions NS, SS and FS, respectively); whatever the 
experimental task the cadence was similar in both groups. 
 
 1.2. Effects of treatment  
 The gait characteristics of PP in each mode of treatment are given in figure 1. 
 
a. Walking Velocity 
 The statistical analysis revealed a global effect of the treatment on walking velocity in 
all experimental condition (chi²=9.41, p<0.01; chi²=17.93, p<0.001 and chi²=15, p<0.01 for 
NS, SS, and FS respectively). Walking velocity increased similarly with levodopa, DBS and 
combination of both compared with the complete OFF state.  
b. Step Length 
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 In the NS condition, we showed a significant global effect of treatment on step length 
(chi²=15.27, p=0.002). Statistical analysis showed a significant increase of the step length in 
the ON/ON state of treatment in comparison with the other states. The SNK post hoc analysis 
revealed a significant decrease of the step length in the OFF/OFF state of treatment as 
compared with the ON/OFF and OFF/ON states of treatment. No significant differences were 
observed between OFF/ON and ON/OFF states, indicating that levodopa and DBS similarly 
improved step length and that the combination of both therapies had an additional effect. 
 In SS and FS, we showed a significant global effect of treatment on step length 
(chi²=15.8, p=0.001 and chi²=11.8, p<0.01, for SS and FS respectively).  The step length was 
significantly shorter in the OFF/OFF state than in the other. No significant differences were 
observed between the states OFF/ON, ON/OFF or ON/ON.  
c. Walking cadence 
In the NS and SS conditions, the walking cadence did not differ significantly between 
all states of treatment. In the SS condition, a significant overall effect of treatment was 
observed (chi²=8.33, p<0.05). The multiple comparisons revealed that the walking cadence 
was significantly lower in the OFF/OFF state of treatment than in the other. 
INSERT FIGURE 1 ABOUT HERE 
 
 1.3 Task effect 
 
a. Walking velocity 
  A significant effect of task was observed in CS (chi2=22, p<0.001) and in 
treated PP (chi²=22, p<0.001; chi²=20, p<0.001 and chi²=18.2, p<0.001 in the 
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OFF/ON, ON/OFF and ON/ON states, respectively): The walking velocity increased 
significantly between SS and FS. Without treatment a significant effect of task was 
also observed in PP (chi²=12.67, p<0.001) but interestingly, no significant difference 
was found between NS and FS, indicating that PP were unable to increase significantly 
their velocity. 
 
b. Step length 
  A significant effect of task on step length was observed in CS (chi²=22, p<0.001) and 
in treated PP, whatever the treatment the step length increased significantly between 
the SS and the FS condition (chi²=22, p<0.001; chi²=16.8, p<0.001 and chi²=14.6, 
p<0.001 in the OFF/ON, ON/OFF and ON/ON states, respectively). In untreated PP a 
significant effect of task was also observed (chi²=11.56, p=0.001), but no significant 
difference was found to exist between NS and FS conditions. 
 
  c. Walking cadence 
 A significant effect of task was observed in CS (chi²=16.55, p<0.001) and in treated 
PP (chi²=16.22, p<0.001; chi²=22, p<0.001; chi²=18.2, p<0.001 and chi²=20, p<0.001  
for  OFF/OFF, OFF/ON, ON/OFF and ON/ON states of treatment, respectively). The 
walking cadence increased significantly between SS, NS and FS.  
 
INSERT FIGURE 2 ABOUT HERE 
2. Speech analysis 
2.1 Effects of Parkinson’s Disease 
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 During NS and SS tasks, speech velocity did not differ significantly between the two 
groups. In the FS task the speech velocity was significantly lower in PP (T=93.5, p<0.05). 
 In the NS task, ISDs’ values were similar in both groups. In the SS task, ISD’s value 
of PP was significantly longer than that of CS (T=160.5, p<0.05); whereas in the FS task, the 
ISD of PP was significantly shorter than that of CS (T=91, p<0.05).  
 In NS and FS tasks, the SPIR did not differ significantly between the two groups. In 
the SS task, the SPIR values of PP were significantly lower than those of CS (T=93, p<0.05).  
 
 
2.2. Effects of treatment  
 In order to assess the effects of treatment, speech performances of PP were compared 
depending on the treatment undergone. The speech performances of PP are given in figure 3.  
 
a. Speech velocity  
 Whatever the experimental condition, no significant differences were observed 
between the four states of treatment. 
b. ISD 
 Concerning the ISD, the Friedman’s ANOVA showed significant differences between 
the four states of treatment during NS (chi2=9.275, p<0.05) and FS condition (chi2=1.175, 
p<0.01) but not during SS condition. ISD increased significantly with levodopa, DBS and 
combination of both therapies as compared with the complete OFF state.  
  
c. SPIR 
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The SPIR did not differ significantly between any of the states of treatment during NS and SS 
conditions. During FS condition, the statistical analysis showed the existence of a significant 
overall effect of treatment on SPIR (chi2=8.46, p<0.05) which were significantly higher in the 
OFF/OFF state of treatment than in the other states. 
 
INSERT FIGURE 3 ABOUT HERE 
2.3 Task effects 
a. Speech velocity 
 A significant effect of task on speech velocity was observed in CS (chi2=16.545, 
p<0.01) and in treated PP (chi²=14.727, p<0.01; chi²=20.182, p<0.001 and 
chi²=14.364, p<0.01 in the OFF/ON, ON/OFF and ON/ON states, respectively): the 
speech velocity increased significantly between the SS and the FS condition. A 
significant effect of task was also observed in the OFF/OFF PP (chi²=17.636, p<0.01): 
speech velocity increased significantly between NS and FS condition, but not between 
SS and NS conditions.  
  
b. ISD 
 A significant effect of task on ISD was found in CS (chi2=13.273, p<0.01) and in 
treated PP (chi²=10.093, p<0.01; chi²=8.727, p<0.05 and chi²=13.273, p<0.01 in the 
OFF/ON, ON/OFF and ON/ON states, respectively): the ISD increased significantly 
between the SS and FS condition. It is worth noting that the increase of the ISD 
between NS and FS was only significant in the ON/ON state of treatment. In PP in the 
OFF/OFF state of treatment, no significant differences were detected.  
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c. SPIR 
A significant effect of task on SPIR was observed in CS (chi2=8.909, p<0.001): the SPIR 
values decreased significantly in this group between SS and NS and between NS and FS. 
No significant effects of task on SPIR were detected in PP. 
INSERT FIGURE 4 ABOUT HERE 
 
3. Correlations between gait and speech parameters 
 In order to measure the strength of association between gait and speech parameters we 
have used the Spearman’s coefficient of correlation. We have correlated gait velocity with 
speech velocity, walking cadence with SPIR and step length with ISD. We have brought 
together all the velocity of tasks executions.  
 
  3.1. Statistical correlations between walking velocity and speech velocity 
 Significant correlations were found to exist between walking and speech velocities in 
CS (r=0.84, p<0.001), in PP in the OFF/OFF (r=0.717, p<0.001), in the ON/OFF (r=0.505, 
p<0.01), and in the OFF/ON states of treatment (r=0.4325, p<0.05) but not in the ON/ON 
sate.  
 
  3.2. Correlations between step length and ISD 
  A significant correlation was found to exist between step length and ISD in CS 
(r=0.609, p<0.001), in PP in the ON/OFF (r=0.486, p<0.01) and ON/ON (r=0.421, p<0.05) 
state of treatment. No statistical correlations were observed in the OFF/OFF and OFF/ON 
states of treatment. 
 
  3.3. Correlations between walking cadence and SPIR 
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 A significant negative correlation was found between walking cadence and SPIR in 
CS (r=-0.702, p<0.001) in PP in the OFF/OFF (r=-0.418, p<0.05) and in the OFF/ON state of 
treatment (r=-0.438, p<0.05), but not in PP in the ON/OFF or ON/ON states of treatment. 
 
DISCUSSION: 
   
Our results demonstrate large similarities between the gait‘s pattern and speech’s 
involvement in PD and in their responses to STN-DBS and levodopa treatment  
 
Gait and speech impairments in PD 
  
 The spatiotemporal gait disorders observed in PD are in line with those previously 
described: without treatment,  walking velocity and step length of PP are decreased while 
walking cadence is not significantly different (Azulay et al., 1996; Morris et al., 1994b; 
Sofuwa et al., 2005).Neither walking velocity nor step length increased when the untreated 
patients were asked to walk as fast as possible,  suggesting that they were unable to regulate 
their step length on the basis of internal control mechanisms. Oppositely, the patients’ internal 
walking cadence regulation process seems to be preserved, since their walking cadence 
increased significantly between SS and NS and between NS and FS. This fundamental 
hypokinetic deficit has previously been described by Morris et al. (1994b).  
 The results of the speech analysis brought to light the existence of speech timing 
disorders showing some analogies with the gait impairments. Without any treatment, PP 
tended to speak more slowly than the CS, their ISD often tended to decrease in comparison 
with the control values, in parallel with the decreasing step length. The SPIR showed some 
similarities with the walking cadence, since it was equal to the control values at NS and FS. 
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Few data are available to compare our results, Canter (1963) and Metter and Hanson (1986) 
observed changing speech velocities in PP. The ISD has often been reported to be shorter in 
PP than in CS during both reading and spontaneous speech (Forrest et al., 1989; Hammen and 
Yorkston, 1996). The speech velocity also changes with the co-existence of bradylalia and 
tachylalia (Gentil et al., 1995). The present results show in addition that the speech velocity of 
PP without treatment did not differ between SS and NS, and that their ISD remained 
unchanged under all the experimental conditions. In line with the changes observed in their 
walking patterns, PP therefore have some difficulty in modulating their speech velocities 
because they are no longer able to internally control the ISD. However, the internal speech 
rhythm regulation processes seem to be also impaired, since the SPIR remained unchanged at 
NS and FS condition. 
 
Effect of levodopa and STN-DBS on gait and speech deficits 
 As regards the patients’ responses to treatment, their walking velocities were greatly 
improved by both STN-DBS and levodopa, probably due to an increase in the step length, 
whereas the walking cadence remained unchanged in NS and FS. In all tasks, no significant 
difference between STN-DBS and levodopa was observed, but a cumulative effect was 
observed in the NS condition. Two previous studies show that STN-DBS, like levodopa, 
improves walking velocity by increasing step length without changing walking cadence (Faist 
et al., 2001; Lubik et al., 2006). These findings suggest that STN-DBS may involve the same 
action mechanisms as levodopa via the dopaminergic basal ganglia loop while the cadence, 
which is a rhythmic parameter, is probably regulated by a non dopaminergic structure.  
 
 Levodopa and STN-DBS had no effect on the patients’ speech velocity but increased 
the ISD. Combined treatment restored the patients’ ability to modulate their ISD. The ISD 
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therefore seems to be the main clinical manifestation of speech akinesia, since this parameter 
is regulated by the dopaminergic basal ganglia loop. The effects of treatment on the SPIR 
were often not significant. This finding probably means that in the case of both speech and 
gait, the rhythm is regulated by a non dopaminergic structure. 
 
Gait and speech deficits in PD: a common feature? 
 
This is the first time that correlations have been made between gait and speech 
parameters in PD. In CS and PP undergoing no treatment or under STN-DBS treatment alone, 
a significant correlation was found between walking velocity and speech velocity. In other 
words, CS and PP who walk faster also speak faster. This outcome seems to be modified by 
levodopa. 
 A significant positive correlation between step length and ISD was also found. This 
confirms that step length and ISD decrease are clinical manifestations of both gait and speech 
akinesia, that they are both responsive to levodopa and STN-DBS and that just as akinesia is 
the main gait deficit, speech akinesia may be the main speech deficit in PD. The negative 
correlation between walking cadence and SPIR in CS underlines the different strategies used 
to modulated gait and speech velocity: to walk faster, CS increase the number of steps they 
make, whereas to speak faster, they decrease the number of speech interpauses and pauses. 
This result suggests that the SPIR is a good index to analyse speech rhythmicity, just as the 
walking cadence is a good index to analyse gait rhythmicity. In PD, a similar phenomenon 
was observed only under levodopa suggesting that walking cadence and SPIR are regulated 
by different non dopaminergic structures and that rhythmic perturbations do not always affect 
speech and gait concurrently, but that they may occur earlier in speech, where a two-fold 
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deficit occurs due to the patients’ inability to internally regulate either the number of pauses 
or the ISD.  
 
 Conclusions: As recently suggested by Moreau et al. (2007), who established that oral 
festinations were correlated with gait festinations in PP, the present results underline several 
common features between gait and speech troubles in PD. The decrease in PPs’ walking 
velocity and speech velocity result from a decrease in step length and ISD: these akinetic 
parameters, which are strongly correlated, are regulated by the dopaminergic basal ganglia 
loop. Walking cadence and SPIR, which are the rhythmic gait and speech parameters, do not 
seem to be regulated by a non dopaminergic structure.  
Experimental studies on animals have shown that the PPN of the MLR (Aziz et al., 
1998) is involved in the regulation of the locomotor rhythm (Garcia-Rill and Skinner, 1988). 
On the basis of our results, we propose an equivalent model for the regulation of the spatial 
and rhythmic parameters of gait and the temporal and rhythmic parameters of speech (figure 
5). Further studies are required to confirm such hypothesis and determine what structures are 
involved.  
INSERT FIGURE 5 ABOUT HERE 
 
Acknowledgements: We are grateful to all the subjects who participated in this study and to 
Dr Jessica Anderson-Blanc for revising the English manuscript.  
 18
 
    
UPDRS Axial score      
patient Sex Age 
Disease 
duration 
OFF stim 
/OFF 
Drug 
OFF 
stim /ON 
drug  
% of 
benefit  of 
L-Dopa 
ON stim 
/OFF 
drug 
% of 
benefit  of 
STN-DBS 
ON stim 
/ON 
drug  
% of benefit  
of STN-
DBS and L-
Dopa 
OFF stim 
/OFFdrug  
OFF 
stim /ON 
drug  
% of 
benefit  of 
L-Dopa 
ON stim 
/OFF 
drug  
% of 
benefit  of 
STN-DBS 
ON stim 
/ON 
drug  
% of 
benefit  of 
STN-DBS 
and L-Dopa 
P1 F 66 11 43 18 58,14 28 34,88 16 62,79 15 6 60,00 10 33,33 5 66,67 
P2 M 60 8 22 0 100,00 6 72,73 1 95,45 5 0 100,00 0 100,00 1 80,00 
P3 M 68 11 15 8 46,67 12 20,00 7 53,33 7 4 42,86 7 0,00 5 28,57 
P4 M 68 16 39 19 51,28 24 38,46 17 56,41 13 8 38,46 12 7,69 8 38,46 
P5 F 63 20 75 20 73,33 31 58,67 18 76,00 20 9 55,00 11 45,00 7 65,00 
P6 F 71 17 27 7 74,07 7 74,07 6 77,78 10 4 60,00 4 60,00 4 60,00 
P7 M 64 12 30 3 90,00 3 90,00 2 93,33 6 1 83,33 0 100,00 0 100,00 
P8 M 69 11 24 9 62,50 10 58,33 6 75,00 9 5 44,44 6 33,33 6 33,33 
P9 M 66 10 33 8 75,76 8 75,76 3 90,91 7 2 71,43 1 85,71 1 85,71 
P10 F 61 20 58 26 55,17 42 27,59 22 62,07 17 10 41,18 14 17,65 9 47,06 
P11 M 54 8 41 8 80,49 8 80,49 6 85,37 9 2 77,78 3 66,67 2 77,78 
Mean  65 13 37 11 70 16 57 9 75 11 5 61 6 50 4 62 
Standar 
deviation  5 4 17 8 17 13 24 7 15 5 3 20 5 35 3 23 
 
Table 1 
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FIGURE CAPTIONS: 
 
TABLE 1: Medical characteristics of the 11 Parkinsonian patients: sex, age and disease 
duration, UPDRS part III and axial scores, effect of L-Dopa and STN in % iof the OFF/OFF 
score, in 4 states of treatment performed at the time of testing. The axial score was the sum of 
items numbers 18, 19, 22, 27, 28, 29 and 30 in the motor UPDRS score.  
 
FIGURE 1: Task effect on gait parameters: From top to the bottom, medians and quartiles of 
walking velocity, step length and walking cadence values recorded in Parkinsonian patients in 
the 3 experimental conditions (from the left to the right) natural speed, slow speed and fast 
speed) in the 4 states of treatment, from left to right: without treatment (OFF/OFF), without 
STN-DBS but with levodopa (OFF/ON), with STN-DBS but without levodopa (ON/OFF) and 
with both STN-DBS and levodopa (ON/ON). 
 
FIGURE 2: Treatment effect on gait parameters: Medians and quartiles of walking velocity, 
step length and walking cadence values recorded in the natural speed (in white), in the slow 
speed (in grey) and in the fast speed (in black) conditions, from left to right: without treatment 
(OFF/OFF), without STN-DBS but with levodopa (OFF/ON), with STN-DBS but without 
levodopa (ON/OFF) and with both STN-DBS and levodopa (ON/ON) and in control subjects 
(CS).  
 
 
FIGURE 3: Task effects on speech parameters : Medians and quartiles of speech velocity, 
ISD and speech index of rythmicity (SPIR) recorded in Parkinsonian patients in the 3 
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experimental conditions (natural speed, slow speed and fast speed) in the 4 states of treatment, 
from left to right: without treatment (OFF/OFF), without STN-DBS but with levodopa 
(OFF/ON), with STN-DBS but without levodopa (ON/OFF) and with both STN-DBS and 
levodopa (ON/ON). 
 
FIGURE 4: Treatment effects on speech parameters : Medians and quartiles of speech 
velocity, ISD and speech index of rythmicity (SPIR) recorded in the natural speed (in white), 
in the slow speed (in grey) and in the fast speed (in black) conditions, from left to right: 
without treatment (OFF/OFF), without STN-DBS but with levodopa (OFF/ON), with STN-
DBS but without levodopa (ON/OFF) and with both STN-DBS and levodopa (ON/ON) and in 
control subjects (CS).  
 
FIGURE 5: Model for the regulation of the spatial and rhythmic parameters of gait (left) and 
the temporal and rhythmic parameters of speech (right). 
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